Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Fundsmith Equity Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"Fundsmith underperformed in 2024 due to extreme market concentration in mega-cap tech stocks, but maintains superior portfolio quality metrics. The fund sold Apple and Diageo while adding Atlas Copco and Texas Instruments."
Fundsmith Equity Fund returned 8.9% in 2024, underperforming the MSCI World Index's 20.8% return due to extreme market concentration where just five stocks provided 45% of S&P 500 returns. The fund maintains its strategy of owning high-quality companies with superior business metrics including 32% return on capital and 64% gross margins, significantly better than market indices. Key detractors included L'Oréal affected by China's economic struggles, IDEXX facing post-pandemic normalization, and Nike dealing with management missteps. Top contributors were Meta, Microsoft, Philip Morris, ADP, and Stryker. The manager sold Apple, Diageo, and McCormick while adding Atlas Copco and Texas Instruments. Portfolio turnover remained low at 3.2%. The fund faces headwinds from index fund flows creating momentum in mega-cap stocks and the AI capital expenditure arms race. Despite near-term challenges, the focus remains on long-term ownership of exceptional businesses, with expectations for improved cash conversion in 2025.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High conviction demonstrated through concentrated portfolio of named positions held for years, specific position sizing discussions, and willingness to hold through underperformance. Manager provides detailed rationale for each holding and explicitly states intention to continue holding quality companies like IDEXX despite pain.
Growth Outlook
The manager expresses caution about market concentration and index fund momentum creating vulnerabilities, while acknowledging the difficulty of timing when current dynamics might reverse. There's concern about AI spending sustainability and tech sector cyclicality.
Risk Appetite
Portfolio remains fully invested in high-quality companies with minimal cash, but the manager is selective about new additions and willing to sell when valuations become stretched, as demonstrated with Apple sale.
Capital Deployment
Minimal net deployment activity with portfolio turnover of only 3.2%. Sold three companies and purchased two, representing rotation rather than significant capital deployment or withdrawal.
Forward Guidance
The manager takes a wait-and-see approach, expecting portfolio cash conversion to improve in 2025 but not providing clear directional guidance on deployment or positioning changes.
Language Signal
Language is balanced but leans slightly cautious with discussions of market vulnerabilities, concentration risks, and potential downturns, though offset by confidence in portfolio quality.
Perceived Risk
Manager identifies multiple specific risks including market concentration, index fund momentum feedback loops, AI capital expenditure sustainability, and sector-specific challenges from weight loss drugs. Risks are discussed in detail with potential impact scenarios.
Opportunity Density
Manager suggests selective opportunities exist, as evidenced by adding two new positions, but emphasizes the challenge of finding attractively valued quality companies in the current environment.
Time Horizon
Explicitly long-term approach with average portfolio company founded in 1920, holding four companies since 2010 inception, and stated intention to hold quality companies through temporary underperformance. Strategy described as patient capital with minimal turnover.
